作为骨髓瘤的新治疗策略,抑制迪斯科丁域受体1是一种新的治疗策略
Jinglu Wang1, Robert L Walker2, Francis J Hornicek2
1Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
概括
在骨髓瘤中,迪斯科伊丁域受体1 (DDR1) 的高表达预示着不良预后和复发. 抑制DDR1会减少癌细胞的生长,这表明它是骨癌的潜在治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生化学
背景情况:
- 骨髓瘤是最常见的原发性骨癌,对复发性或转移性疾病的治疗选择有限.
- 迪斯科伊丁域受体1 (DDR1),一个原激活的氨酸激酶,与癌症进展有关,促进细胞粘附,增殖,迁移和转移.
研究的目的:
- 为了研究骨髓瘤组织中DDR1的表达水平.
- 确定DDR1表达与患者结果和化疗反应有关的临床预后意义.
- 阐明DDR1在骨髓瘤细胞生长,扩散和转移中的功能作用.
主要方法:
- 在骨髓瘤样本的组织微阵列 (TMA) 上进行免疫组织化学染色,以评估DDR1表达.
- 利用DDR1特异性siRNA和选择性抑制剂 (7rh) 来评估DDR1对细胞增殖和生长的影响.
- 采用克隆基因分析和3D细胞培养模型来评估DDR1抑制效应在体外和体外类似条件下.
主要成果:
- 增加的DDR1表达显着与骨髓瘤患者的复发,转移和减少整体存活率有显著的相关性.
- 较高的DDR1水平与患者对新辅助化疗的反应相反相关.
- 抑制或抑制DDR1可以明显降低骨髓瘤细胞的增殖和生长.
结论:
- DDR1表达是骨髓瘤预后不佳的独立预测因子.
- 针对DDR1是一种有前途的治疗策略,用于治疗骨髓瘤,特别是在晚期或复发的病例中.
相关概念视频
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K